NovoSeven RT (Intravenous)
Generic name:coagulation factor viia (intravenous route) [ koh-a-gyoo-LAY-shun-FAK-tor-SEV-en-A ]
Drug class:Miscellaneous coagulation modifiers
Medically reviewed by Drugs.com. Last updated on May 14, 2022.
Serious arterial and venous thrombotic events are associated with the use of coagulation factor VIIa. Patients should be advised of the risks and know the signs and symptoms of thrombotic and thromboembolic events. Monitor for signs/symptoms of thrombosis and of activation of the coagulation cascade .
Intravenous route(Powder for Solution)ThrombosisSerious arterial and venous thrombotic events may occur following administration of coagulation factor VIIa recombinant-jncw.Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive coagulation factor VIIa (recombinant)-jncw.Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis .
Commonly used brand name(s)
In the U.S.
- Novoseven
- NovoSeven RT
- Sevenfact
Available Dosage Forms:
- Powder for Solution
Therapeutic Class: Hemostatic
Uses for NovoSeven RT
Factor VIIa is used to treat and prevent bleeding episodes in patients with Hemophilia A or B who have formed antibodies against other clotting proteins (eg, Factor VIII or Factor IX) that help bleeding to stop. It is also used to treat or prevent bleeding in patients with acquired hemophilia, congenital Factor VII deficiency, or Glanzmann's thrombasthenia (a bleeding disorder that is caused by a blood abnormality) that has been treated with platelet transfusions but did not work well.
Factor VIIa is a man-made protein produced to replicate the naturally occurring activated factor VII (factor VIIa) in the body. It is used to stop bleeding of injuries for patients with hemophilia by helping the blood to clot.
Factor VIIa is to be given only by or under the direct supervision of your doctor.
Before using NovoSeven RT
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of Factor VIIa in children.
Geriatric
Adequate and well-controlled studies have not been done on the relationship of age to the effects of Factor VIIa in geriatric patients.
Breastfeeding
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking th
